Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on June 18, 2018. The filing addresses corporate governance changes and regulatory compliance status regarding the company's listing on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses on corporate events rather than financial performance data.
Material Changes and Corporate Events
- Board Expansion: The Board of Directors increased its size from six to eight directors.
- New Director Appointment: Mr. David MacNaughtan was appointed as a Class III director on June 18, 2018, serving until the 2021 annual meeting. He was selected by Sagard Capital Partners, L.P., holder of Series A Convertible Participating Preferred Stock, exercising its director election rights.
- Nasdaq Compliance: The company previously faced delisting risks due to stock price and stockholders' equity deficiencies. On June 18, 2018, Nasdaq notified the company that the minimum stockholders' equity deficiency had been cured.
- Listing Status: The pending hearing regarding potential delisting was cancelled as moot, and Nasdaq determined to continue the listing of the company's securities.
Outlook, Risks, and Management Commentary
Management highlighted Mr. MacNaughtan's extensive experience in specialty finance and the pharmaceutical industry, including roles at CPPIB Credit Investments Inc. and DRI Capital, as a key qualification for his directorship. The resolution of the Nasdaq equity deficiency removes the immediate risk of delisting associated with that specific metric.
Investor Verification Checklist
- Verify the terms of the Series A Convertible Participating Preferred Stock and Sagard Capital Partners' ongoing influence on board composition.
- Confirm the specific actions taken to cure the minimum stockholders' equity deficiency to ensure long-term compliance.
- Review the press release filed as Exhibit 99.1 for additional details on the board appointment.
- Monitor future filings for any remaining Nasdaq compliance issues related to bid price requirements.